Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1027-1028; doi:10.1093/jnci/95.14.1027
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Thompson, I.
Right arrow Articles by Naylor, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, I.
Right arrow Articles by Naylor, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1027-1028, July 16, 2003
© 2003 Oxford University Press

EDITORIAL

Prostate Cancer and Prostate-Specific Antigen: The More We Know, the Less We Understand

Ian Thompson, Robin J. Leach, Brad H. Pollock, Susan L. Naylor

Affiliations of authors: I. Thompson (Division of Urology, Department of Surgery), R. J. Leach, S. L. Naylor (Department of Cellular and Structural Biology), B. H. Pollock (The Center for Epidemiology and Biostatistics), University of Texas Health Science Center at San Antonio, and the Prostate Cancer Program, San Antonio Cancer Institute, San Antonio, TX.

Correspondence to: Ian M. Thompson, M.D., Division of Urology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229 (e-mail: thompsoni@uthscsa.edu).

The first 10% of the full text of this article appears below.

Since its discovery in 1979, prostate-specific antigen (PSA) has revolutionized the way we manage prostate cancer (1). Prior to the discovery of PSA, prostate cancer was detected either by digital rectal examination (although only one-third of cases are typically organ-confined) or when a patient presented with inanition, pain, or a pathologic fracture (2). Physicians of the pre-PSA era had no way to reliably detect the disease early. The discovery of PSA changed all of that. Results of initial studies of PSA in patients with prostate cancer suggested that PSA was . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
E. KALAY, A. ERGEN, F. NARTER, B. AGACHAN, U. GORMUS, N. YIGIT, and T. ISBIR
ARE-I Polymorphism on PSA Gene in Prostate Cancer Patients of a Turkish Population
Anticancer Res, April 1, 2009; 29(4): 1395 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Lai, M.-A. Kedda, K. Hinze, R. L.G. Smith, J. Yaxley, A. B. Spurdle, C.P. Morris, J. Harris, and J. A. Clements
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility
Carcinogenesis, May 1, 2007; 28(5): 1032 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
D. M. Werny, M. Saraiya, and E. W. Gregg
Prostate-specific Antigen Values in Diabetic and Nondiabetic US Men, 2001-2002
Am. J. Epidemiol., November 15, 2006; 164(10): 978 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-R. Li, J. Wang-Rodriguez, T. M. Nair, J. M. Yeakley, Y.-S. Kwon, M. Bibikova, C. Zheng, L. Zhou, K. Zhang, T. Downs, et al.
Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens.
Cancer Res., April 15, 2006; 66(8): 4079 - 4088.
[Abstract] [Full Text] [PDF]